Immune-related myocarditis due to combination use of nivolumab and ipilimumab
10.3760/cma.j.cn114015-20190513-00416
- VernacularTitle:联合应用纳武单抗与伊匹木单抗致免疫相关性心肌炎
- Author:
Min WEI
1
;
Zongling XIA
Author Information
1. 江苏省常州市第一人民医院药剂科 213003；广西壮族自治区平南县第二人民医院药剂科 537307
- Publication Type:Journal Article
- Keywords:
Antineoplastic agents, immunological;
Nivolumab;
Ipilimumab;
Cardiotoxicity;
Myocarditis
- From:
Adverse Drug Reactions Journal
2020;22(9):527-528
- CountryChina
- Language:Chinese
-
Abstract:
A 63-year-old male patient with lung metastases from bladder cancer received IV infusions of nivolumab (1 mg/kg) and ipilimumab (3 mg/kg) once every 21 d. On day 3 after the second medication, the patient developed paroxysmal chest tightness, which could be self-mitigated by lying down for several minutes. Laboratory tests showed high-sensitive troponin Ⅰ 4 340 ng/L and creatine kinase (CK)-MB 98.9 μg/L. Immune-related myocarditis due to combination use of nivolumab and ipilimumab was considered. After methylprednisolone with prednisone sequentially and symptomatic and supportive treatments such as fluid infusion, liver and stomach protection, improvement of myocardial metabolism, and reduction of oxygen consumption, the patient′s symptoms were improved obviously. Laboratory tests showed high-sensitive troponin Ⅰ 192 ng/L and CK-MB 28.4 μg/L.
